Stock market update: Nifty Pharma index advances 0.66%
ADVERTISEMENT Shares of Laurus Labs Ltd.(up 3.95 per cent), Biocon Ltd.(up 2.46 per cent), Zydus Lifesciences Ltd.(up 1.41 per cent), Divi's Laboratories Ltd.(up 1.36 per cent) and Granules India Ltd.(up 1.26 per cent) ended the day as top gainers in the pack.
On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 1.47 per cent), Lupin Ltd.(down 0.26 per cent), Dr. Reddy's Laboratories Ltd.(down 0.14 per cent), Ipca Laboratories Ltd.(down 0.12 per cent) and Aurobindo Pharma Ltd.(down 0.1 per cent) finished as the top losers of the day.
The Nifty Pharma index closed 0.66 per cent up at 21826.8. Benchmark NSE Nifty50 index ended up 100.16 points at 25103.2, while the BSE Sensex stood up 256.22 points at 82445.21. Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red.
ADVERTISEMENT
Shares of Vodafone Idea, JP Power, Reliance Power, Suzlon Energy and Capri Global were among the most traded shares on the NSE.
Shares of Indef Manufacturing, Hybrid Financial Services, TVS Electronics, Sudarshan Chemical and MCX India hit their fresh 52-week highs in today's trade, while Shree Ram Proteins, Varanium Cloud, Techindia Nirman, BSL Ltd and United Drilling hit their fresh 52-week lows.
ADVERTISEMENT
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Two Trades for Today: A cement major for a 6.5% upmove, a large-cap metal & mining stock for almost 7% gain
The markets extended their weakness after a brief respite and ended on a negative note on Friday. The Nifty started on a flat note; however, it once again formed the high point of the day in the early minutes of the trade. The markets experienced strong selling pressure in the first hour of the session, during which time they also reached their low point of the day. The remainder of the session was spent in a capped range. With no signs of FONT SIZE SAVE PRINT COMMENT
Indian Express
4 hours ago
- Indian Express
Share price under Rs 200: Multibagger railway stock secured over Rs 1600 crore order last week
Multibagger railway stock order win: A multibagger railway PSU stock secured back-to-back orders last week, according to exchange filings. The total value of these new contracts exceeds Rs 1,600 crore. Can you guess which one? Here's a hint – as of July 20 (NSE data), this railway company has a market capitalisation of Rs 17,563.19 crore. This railway company is none other than IRCON International Limited. IRCON is a navratna company under the Ministry of Railways. Last week (July 14-18), IRCON bagged three new orders. These are as follows: In an exchange filing on July 18, the company said, 'Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-233, Line-6, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing and Commissioning of Power Supply and Traction, E & M, Lifts & Escalators including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability Maintenance Period of Line 6 [Swami Samarth Nagar to Vikhroli (EEH)] of Mumbai Metro Rail Project of MMRDA.' The project cost is Rs 642,44,02,451.34. In a separate filing, the railway company said, ' Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-239, Line-5, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing And Commissioning of 220 kV receiving Substation Including 220 kV, 33kV & 25kV Cabling Work, Complete 25kV Overhead Catenary System along with switching station, 33kV Auxiliary Power Distribution System Including 33/0.415 kV Auxiliary Sub-Station (ASS) And Complete SCADA System, Electrical and Mechanical works, Lift & Escalator Works for part of Main Line, Stations & Kasheli Depot of Mumbai Metro Rail Line 5 Project of MMRDA Including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability and Maintenance Period.' The project cost is Rs 471,29,72,820. In a filing on Friday, the company said, ' IRCON has been awarded with Letter of Award for the project floated by RVNL (Participated in this bid in JV mode with M/s JPWIPL (i.e., IRCON – 70% & JPIWL – 30%).' Here the total project amount is Rs 755,78,21,993.63 (IRCON Share – Rs 529,04,75,395.53),' the company said. Shares of IRCON closed in red on Friday (July 18). The PSU railway stock settled at Rs 186.74 apiece, down 1.60 per cent on NSE. IRCON International Limited is a component of the BSE 500. According to the BSE analytics (as of July 20), shares of IRCON gave negative returns in the last 1 week and 2 weeks, by 2.20 per cent and 6.27 per cent, respectively. Shares of the PSU railway stock also fell in the last 1 year by 40.25 per cent. However, in the past 2 years, 3 years, and 5 years, shares of the company rose 116.15 per cent, 405.27 per cent, and 307.03 per cent, respectively. This year, IRCON paid a dividend of Rs 1.65 in February. Last year, the PSU railway stock declared total dividends of Rs 3.10. IRCON issued bonuses in the ratio of 1:1 for the equity shareholders.
Economic Times
4 hours ago
- Economic Times
Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
Anthem Biosciences is set to debut on the stock exchanges on Monday, July 21. In the unlisted market, its shares are trading at a premium of Rs 165–170, indicating a potential listing gain of around 29% over the IPO price of Rs 570 (upper band). ADVERTISEMENT While the grey market premium (GMP) reflects strong investor interest, it remains a speculative indicator and can change quickly before listing. The Rs 3,395 crore IPO was entirely an offer for sale (OFS) and closed on July 16. It witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. The issue was priced in a band of Rs 540–570 per share, with a minimum lot size of 26 shares. The stock will list on both NSE and BSE. Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics).Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which constitute a large portion of its client base. Since its inception, the company has served over 675 clients and completed more than 8,000 projects. ADVERTISEMENT In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is currently expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ADVERTISEMENT JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar for the issue. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
